<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933698</url>
  </required_header>
  <id_info>
    <org_study_id>AMOXIPED-01</org_study_id>
    <secondary_id>63.064.653/0001-54</secondary_id>
    <nct_id>NCT01933698</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Commercial Amoxicillin Suspensions</brief_title>
  <official_title>Bioequivalence Study of Two Commercial Amoxicillin Suspension Formulations in Healthy Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to compare the pharmacokinetic profiles and to evaluate the&#xD;
      bioequivalence of two commercial amoxicillin-suspension formulations in healthy Brazilian&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Under fasting condition, 25 volunteers (13 males and 12 females) were included in this&#xD;
      randomized, open-label, two-period crossover (1-week washout interval) bioequivalence study.&#xD;
      Blood samples were collected at pre-dose (0h) and 0.5, 1, 1.33, 1.66, 2, 2.5, 3, 4, 6, 8 and&#xD;
      12 hours after drug ingestion. Pharmacokinetic parameters (Cmax, Tmax, T1/2,&#xD;
      Area-under-curve0-12h and Area-under-curve0-inf) were calculated from plasma concentrations&#xD;
      for both formulations in each subject.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in plasmatic amoxicillin concentrations along time measured by HPLC.</measure>
    <time_frame>Change from baseline to 12 hours</time_frame>
    <description>Amoxicillin were extracted from plasma by precipitating plasma proteins with acetonitrile. Amoxicillin plasmatic concentration was accessed every 30 minutes until 3h hours after drug administration and every 2h after this time until 12h of drug administration. Drug plasmatic concentrations were obtained by using a HPLC method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Bioequivalence of Amoxicillin</condition>
  <arm_group>
    <arm_group_label>Amoxi-Ped</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
    <description>Comparison of pharmacokinetics of both formulations</description>
    <arm_group_label>Amoxi-Ped</arm_group_label>
    <arm_group_label>Amoxil</arm_group_label>
    <other_name>Amoxil</other_name>
    <other_name>Amoxi-Ped</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  negative to HIV, hepatitis B virus, hepatitis C virus, addictive drugs and pregnancy&#xD;
             test for women&#xD;
&#xD;
          -  age between 19 and 46 years&#xD;
&#xD;
          -  weight between 52 and 85 kg and body mass index between 17.6 and 28.4kg/m2&#xD;
&#xD;
          -  ability to provide written consent&#xD;
&#xD;
          -  laboratory exam results within the normal range for healthy individuals and/or&#xD;
             medically acceptable defined by a clinical investigator;&#xD;
&#xD;
          -  feeding habits consistent with the standardization of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  history of hypersensitivity to penicillins (normal or idiosyncratic drug reaction)&#xD;
&#xD;
          -  any evidence of dysfunction or clinically significant deviation from normal&#xD;
&#xD;
          -  history of any psychiatric illness that might compromise the ability to provide&#xD;
             written consent&#xD;
&#xD;
          -  history of gastrointestinal disease, hepatic, renal, pulmonary, cardiovascular,&#xD;
             hematological, neurological or diabetes or glaucoma&#xD;
&#xD;
          -  active smoker&#xD;
&#xD;
          -  consumption of more than 5 cups of coffee or tea per day&#xD;
&#xD;
          -  history of drug dependence or abuse of alcohol consumption&#xD;
&#xD;
          -  use of enzymatic-inducers drugs within 30 days or any systemic medication (including&#xD;
             prescription drugs, such as painkillers, hepatoprotective, influenza, etc) within 14&#xD;
             days before the start of the study&#xD;
&#xD;
          -  participation in any clinical study in 9 weeks prior to the study&#xD;
&#xD;
          -  have lost or donated more than 350 mL of blood in the last three months&#xD;
&#xD;
          -  have been subjected to abnormal diet for any reason (therapeutic, aesthetic,&#xD;
             religious, etc.)&#xD;
&#xD;
          -  did not have adequate venous access.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco C Groppo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas, Brazil</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana PP Cione, Chem.</last_name>
    <role>Study Chair</role>
    <affiliation>BIOAGRI Laboratórios Ltda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BIOAGRI Laboratórios Ltda</name>
      <address>
        <city>Piracicaba</city>
        <state>SP</state>
        <zip>13412-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Baglie S, Rosalen PL, Franco LM, Ruenis AP, Baglie RC, Franco GC, Silva P, Groppo FC. Comparative bioavailability of 875 mg amoxicillin tablets in healthy human volunteers. Int J Clin Pharmacol Ther. 2005 Jul;43(7):350-4.</citation>
    <PMID>16035378</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2013</study_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Francisco Groppo</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Human</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

